Posted by Michael Wonder on 07 Apr 2022
CMS finalises Medicare coverage policy for monoclonal antibodies directed against amyloid for the treatment of Alzheimer’s disease
7 April 2022 - Today, the CMS released a national policy for coverage of aducanumab (Aduhelm) and any future monoclonal antibodies directed against amyloid approved by the FDA with an indication for use in treating Alzheimer’s disease.
From the onset, CMS ran a transparent, evidence based process that incorporated more than 10,000 stakeholder comments and more than 250 peer-reviewed documents into the determination.
